Idiopathic Pulmonary Fibrosis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Idiopathic Pulmonary Fibrosis remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 381 matched trial records and 316 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600127821 | Intervention not normalized | Not Applicable; Not yet recruiting | Sponsor not listed | China | Pulmonary Artery Systolic Pressure, PASP; Serum chemerin levels (before medication treatment) | 2026-09-30 |
| NCT07687459 | Rentosertib | Phase 3; Not yet recruiting | InSilico Medicine Hong Kong Ltd. | China | the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks. (Weeks 0,4,12,26,39,52) | 2029-10-30 |
| NCT07682337 | Intervention not normalized | Phase 1; Not yet recruiting | Sponsor not listed | Australia | Incidence and frequency of adverse events, adverse drug reactions, serious adverse events, and serious adverse drug reactions (From first dose through Post-Study Visit (up to Day 33)); For Physical examination to evaluate General Appearance (From first dose through Post-Study Visit (up to Day 33)) | 2027-06-01 |
| NCT07679893 | Nintedanib esylate | Phase 2; Recruiting | MannKind Corp. | Canada, United States | Safety and Efficacy (From enrollment to the end of randomized treatment at 12 weeks); Events of clinical bronchospasm (From enrollment to the end of open-label treatment at 36 weeks) | 2028-01-30 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF) (Phase 2): the indexed record reports Relative Change From Baseline in 24-hour Cough Frequency at Week 6(Least Squares Mean) = -0.19 percent change (Standard Error, 0.173); Relative Change From Baseline in 24-hour Cough Frequency at Week 6(Least Squares Mean): Least square (LS) mean difference = -0.71(95% CI, -1.17 to -0.25), P-Value = 0.0028; Least square (LS) mean difference = -1.08(95% CI, -1.55 to -0.61), P-Value = 0.0000; Least square (LS) mean difference = -1.14(95% CI, -1.61 to -0.67), P-Value = 0.0000; Relative Change From Baseline in 24-hour Cough Frequency at Week 6(Least Squares Mean) = -1.27 percent change (Standard Error, 0.176).
- LONG-TERM FUNCTIONAL TRAJECTORIES AND TREATMENT RETENTION WITH NINTEDANIB IN IPF AND PROGRESSIVE SARD-ILD (Not Applicable): the indexed record reports DLCO(percent predicted) = -0.049 %; DLCO(percent predicted) = -0.29 %.
- Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (Phase 3): the indexed record reports Clinical worsening = 44.5 %; Clinical worsening = 31.8 %.
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Rentosertib (Phase 3; TNIK), Nintedanib esylate (Approved; CSF-1R x FGFRs x FLT3). Company & Deal Intelligence records identify sponsor context for InSilico Medicine Hong Kong Ltd. (3696), MannKind Corp. (MNKD). Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Idiopathic Pulmonary Fibrosis has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
